The US Justice Department has rejected a $1 billion settlement offer by Johnson & Johnson over allegations that it marketed Risperdal for unapproved uses.
Various media outlets are reporting that the federal government is instead asking for $1.8 billion to settle civil claims by the government and others over the alleged unsanctioned marketing.
Risperdal and its generic forms are approved by the Food & Drug Administration for use in treatment of bipolar disorder, schizophrenia, and autism. Lawsuits by state and federal governments claim Johnson & Johnson has marketed Risperdal for unapproved uses, such as for the treatment of dementia in the elderly.
J&J has already paid out millions after lawsuits over the allegations, including $158 million to Texas, $327 million to South Carolina, and $258 million to Louisiana.
Al Wasilewski, a J&J press officer, told PRWeek that the company is not putting a communications plan in place to discuss the matter with the public, and it does not plan to comment on the case.